3,6-dimethyl-1H-quinazoline-2,4-dione | 176959-87-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3,6-dimethyl-1H-quinazoline-2,4-dione
• CAS: 176959-87-8
• 化学式: C₁₀H₁₀N₂O₂
• 分子量: 190.202
• InChiKey: AQAPHXYFLMFEGM-UHFFFAOYSA-N

物化性质

• 密度：
  1.246±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,6-dimethyl-1H-quinazoline-2,4-dione 在 lithium aluminium tetrahydride 、 间戊二烯 、 三氟甲磺酸 、 氨 、 叔丁醇 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 5.58h， 生成 (1S,9R,12R)-6-methoxy-9,15-dimethyl-13,15-diazatetracyclo[7.7.1.01,12.03,8]heptadeca-3(8),4,6-triene
  参考文献：
  名称：

  Asymmetric Syntheses, Opioid Receptor Affinities, and Antinociceptive Effects of 8-Amino-5,9-methanobenzocyclooctenes, a New Class of Structural Analogues of the Morphine Alkaloids

  摘要：

  Several 8-amino-5,9-methanobenzocyclooctenes have been prepared by asymmetric organic synthesis techniques. Opioid receptor affinity studies have revealed the virtual absence of enantioselectivity for receptor binding, particularly at the mu-receptor, for the (+)-3a-f and the (-)-3a-f series. It is noteworthy that inversion of configuration at the nitrogen-bearing carbon atom [(5S,8S,9S)-8-amino-3-hydroxy-5,9-methano-9-(methoxymethyl)-5-methylbenzocyclooctene, (+)-3a vs (5S,8S,9R)-8-amino-3-hydroxy-5,9-methanoxymethyl)-5-methylbenzocyclooctene, (dl)-22] resulted in a >10-fold increase in kappa-receptor affinity. Antinociceptive studies demonstrated that (dl)-22 was a full kappa-agonist while (+)-3a and (-)-3a did not possess kappa-activity. Although both (dl)-22 and (+)-3a/(-)-3a had high affinity for the mu-receptor, these compounds did not act as high-affinity agonists or antagonists at this receptor.

  DOI：

  10.1021/jm950817g
• 作为产物：
  描述：

  2-氨基-5-甲基苯甲酸 、 异氰酸甲酯 在 硫酸 作用下， 生成 3,6-dimethyl-1H-quinazoline-2,4-dione
  参考文献：
  名称：

  Asymmetric Syntheses, Opioid Receptor Affinities, and Antinociceptive Effects of 8-Amino-5,9-methanobenzocyclooctenes, a New Class of Structural Analogues of the Morphine Alkaloids

  摘要：

  Several 8-amino-5,9-methanobenzocyclooctenes have been prepared by asymmetric organic synthesis techniques. Opioid receptor affinity studies have revealed the virtual absence of enantioselectivity for receptor binding, particularly at the mu-receptor, for the (+)-3a-f and the (-)-3a-f series. It is noteworthy that inversion of configuration at the nitrogen-bearing carbon atom [(5S,8S,9S)-8-amino-3-hydroxy-5,9-methano-9-(methoxymethyl)-5-methylbenzocyclooctene, (+)-3a vs (5S,8S,9R)-8-amino-3-hydroxy-5,9-methanoxymethyl)-5-methylbenzocyclooctene, (dl)-22] resulted in a >10-fold increase in kappa-receptor affinity. Antinociceptive studies demonstrated that (dl)-22 was a full kappa-agonist while (+)-3a and (-)-3a did not possess kappa-activity. Although both (dl)-22 and (+)-3a/(-)-3a had high affinity for the mu-receptor, these compounds did not act as high-affinity agonists or antagonists at this receptor.

  DOI：

  10.1021/jm950817g

文献信息

• [EN] INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF<br/>[FR] DÉRIVÉS DE L'INDOLIZINE, PROCÉDÉ POUR LEUR PRÉPARATION, ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：SANOFI SA

  公开号：WO2012004731A1

  公开（公告）日：2012-01-12

  The invention relates to compounds corresponding to formula (I): N R1 O R3 R4 R2 (I) in which - R3 and R4 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of formula (A), (B) or (C) below: N N O O Ra Ra' N N O Rb Rb' N O Rc Rc'' Rc' (A) (B) (C) in which the wavy lines represent the phenyl nucleus to which R3 and R4 are attached. Preparation process and therapeutic use.

  该发明涉及与以下式（I）相对应的化合物：N R1 O R3 R4 R2（I），其中- R3和R4与它们附着的苯环的碳原子一起形成一个与下面的式（A）、（B）或（C）之一相对应的6元氮杂环：N N O O Ra Ra' N N O Rb Rb' N O Rc Rc'' Rc'（A）（B）（C），其中波浪线代表R3和R4附着的苯环。制备过程和治疗用途。
• [EN] IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF<br/>[FR] DÉRIVÉS DE L'IMIDAZOPYRIDINE, PROCÉDÉ POUR LEUR PRÉPARATION, ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：SANOFI SA

  公开号：WO2012004732A1

  公开（公告）日：2012-01-12

  The invention relates to compounds corresponding to formula (I): R4 NN R1 O R2 R3 (I) 5 6 7 8 in which - R2 and R3 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of formula (A), (B) or (C) below: N N O O Ra Ra' N N O Rb Rb' N O Rc Rc'' Rc' (A) (B) (C) in which the wavy lines represent the phenyl nucleus to which R2 and R3 are attached. Preparation process and therapeutic use.

  该发明涉及与以下式（I）相对应的化合物：R4 NN R1 O R2 R3（I）其中-R2和R3与它们连接的苯环的碳原子一起形成一个6元杂氮环，该环对应于以下式（A）、（B）或（C）之一：N N O O Ra Ra' N N O Rb Rb' N O Rc Rc'' Rc'（A）（B）（C）其中波浪线代表连接R2和R3的苯环。制备过程和治疗用途。
• [EN] THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES<br/>[FR] UTILISATION THÉRAPEUTIQUE DE DÉRIVÉS D'IMIDAZOPYRIDINE
  申请人：SANOFI SA

  公开号：WO2013102860A1

  公开（公告）日：2013-07-11

  The invention relates to the use of compounds corresponding to formula (I) in which R2 and R3 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of the formulae (A), (B) and (C) in which the wavy lines represent the phenyl nucleus to which R2 and R3 are attached, or of a pharmaceutically acceptable salt thereof, for preparing a medicament for the treatment of bladder cancer.

  该发明涉及使用符合式(I)的化合物，其中R2和R3共同形成与它们附着的苯环的碳原子一起，对应于式(A)、(B)和(C)之一的6元氮杂环，其中波浪线代表R2和R3附着的苯环，或其药学上可接受的盐，用于制备治疗膀胱癌的药物。
• PLATELET ADP RECEPTOR INHIBITORS
  申请人：SCARBOROUGH ROBERT M.

  公开号：US20080194597A1

  公开（公告）日：2008-08-14

  Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.

  化合物的式子(I)到(VIII)，其中更特别地包括磺酰脲衍生物、磺酰硫脲衍生物、磺酰胍衍生物、磺酰氰胍衍生物、硫代酰基磺酰胺衍生物和酰基磺酰胺衍生物，这些衍生物是有效的血小板ADP受体抑制剂。这些衍生物可以用于各种制药组合物中，特别是对于预防和/或治疗心血管疾病，特别是与血栓形成有关的疾病非常有效。本发明还涉及一种预防或治疗哺乳动物血栓形成的方法，包括给予化合物的式子(I)到(VIII)或其药学上可接受的盐的治疗有效量。
• INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：Alcouffe Chantal

  公开号：US20130116249A1

  公开（公告）日：2013-05-09

  The invention relates to compounds corresponding to formula (I): in which R 3 and R 4 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of formula (A), (B) or (C) below: in which the wavy lines represent the phenyl nucleus to which R 3 and R 4 are attached. Preparation process and therapeutic use.

  本发明涉及与式(I)相对应的化合物： 其中，R3和R4与它们所连接的苯环的碳原子一起形成一个6元氮杂环，该环对应于下列式之一：(A)、(B)或(C)式： 其中，波浪线代表连接R3和R4的苯环。 该化合物的制备过程和治疗用途。